Aura Biosciences, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-09-11$6.64 RISE2026-01-20$4.97 PEAK2026-04-14$7.09 215d | -25.2% 131d | Missed | Missed | — | — | +42.7% 84d | Missed |
DROP2025-08-13$7.23 RISE2025-11-20$5.35 PEAK2025-11-28$6.60 107d | -26.0% 99d | Missed | Missed | — | — | +23.4% 8d | Missed |
DROP2025-08-13$7.23 RISE2025-11-07$5.35 PEAK2025-11-28$6.60 107d | -26.0% 86d | Missed | Missed | — | — | +23.4% 21d | Missed |
DROP2025-01-03$8.45 RISE2025-05-14$4.90 PEAK2025-07-25$7.23 203d | -42.0% 131d | Missed | Missed | — | — | +47.6% 72d | Missed |
DROP2024-11-29$9.31 RISE2025-04-10$4.97 PEAK2025-06-10$6.97 193d | -46.6% 132d | Missed | Missed | — | — | +40.2% 61d | Missed |
DROP2024-07-26$10.36 RISE2024-10-09$8.32 PEAK2024-10-18$11.74 84d | -19.7% 75d | Missed | Missed | — | — | +41.1% 9d | Missed |
DROP2024-07-26$10.36 RISE2024-09-03$7.39 PEAK2024-10-18$11.74 84d | -28.7% 39d | Missed | Missed | — | — | +58.9% 45d | Missed |
DROP2024-07-26$10.36 RISE2024-08-22$7.39 PEAK2024-10-18$11.74 84d | -28.7% 27d | Missed | Missed | — | — | +58.9% 57d | Missed |
DROP2024-03-01$9.24 RISE2024-06-25$6.81 PEAK2024-07-26$10.36 147d | -26.3% 116d | Missed | Missed | — | — | +52.1% 31d | Missed |
DROP2024-03-01$9.24 RISE2024-04-17$7.03 PEAK2024-07-15$8.99 136d | -23.9% 47d | Missed | Missed | — | — | +27.9% 89d | Missed |
DROP2023-11-06$11.00 RISE2024-03-18$7.09 PEAK2024-03-21$8.55 136d | -35.5% 133d | Missed | Missed | — | — | +20.6% 3d | Missed |
DROP2023-11-03$11.98 RISE2024-01-24$7.48 PEAK2024-03-01$9.24 119d | -37.6% 82d | Missed | Missed | — | — | +23.5% 37d | Missed |
DROP2023-07-13$12.38 RISE2023-11-09$7.02 PEAK2023-12-27$9.09 167d | -43.3% 119d | Missed | Missed | — | — | +29.5% 48d | Missed |
DROP2022-11-30$14.28 RISE2023-04-05$8.51 PEAK2023-06-06$13.33 188d | -40.4% 126d | Missed | Missed | — | — | +56.6% 62d | Missed |
DROP2022-09-28$18.35 RISE2022-12-28$9.86 PEAK2023-02-07$12.11 132d | -46.3% 91d | Missed | Missed | — | — | +22.8% 41d | Missed |
1–15 / 19 1 / 2 | |||||||
Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen’s se
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladde
BOSTON, May 12, 2026 -- Aura Biosciences, Inc. , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced...
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.39) by 28.21 percent. This is a 9.09 percent increase over losses of $(0.55) per share from
A Late-Stage Company With a Global Oncology Portfolio May 2026 Corporate Presentation Accelerating a differentiated...
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors ...
BOSTON, May 05, 2026 -- Aura Biosciences, Inc. , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the...
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like Cabaletta Bio Inc, Celcuity Inc, and Xerox Holdings Corp.
Aura Biosciences Inc:Aura Biosciences announces pricing of $260 million public offering of common stock and pre-funded warrants Aura Biosciences Inc - offering price set at $6.00 per share and...
Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten
US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 results, cuts FY guidance. Other stocks also down.
Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten
Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed
BOSTON, May 04, 2026 -- Aura Biosciences, Inc. , a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the...
Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of...
HC Wainwright & Co. analyst Andrew S. Fein maintains Aura Biosciences (NASDAQ:AURA) with a Buy and raises the price target from $22 to $24.
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AURA | +6.56% | +21.66% | +37.06% | +27.47% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.59% | +27.38% | +40.51% | +14.79% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 964.7K | $6.45M | 0.00% | Added+4.1% | 2026-03-31 |
| Wellington | fundamental | 127.5K | $853.26K | 0.00% | Trimmed-9.5% | 2026-03-31 |
| RenTech | quant | 102.1K | $683.05K | 0.00% | Trimmed-29.7% | 2026-03-31 |
| Citadel | multi-strat | 21.7K | $145.23K | 0.00% | Trimmed-60.3% | 2026-03-31 |
| FidelityFMR | fundamental | 2.9K | $19.36K | 0.00% | Trimmed-64.4% | 2026-03-31 |
| TRowePrice | fundamental | 415.2K | $2.78K | 0.00% | Trimmed-6.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.37 | — | — |
| 2026-05-11 | -0.40 | -0.50 | -25.79% |
| 2026-03-30 | -0.43 | -0.37 | +13.45% |
| 2025-11-13 | -0.47 | -0.40 | +14.44% |
| 2025-08-13 | -0.47 | -0.47 | +1.05% |
| 2025-05-15 | -0.49 | -0.55 | -11.79% |
| 2025-03-24 | -0.44 | -0.52 | -17.29% |
| 2024-11-12 | -0.44 | -0.42 | +4.55% |
| 2024-08-08 | -0.45 | -0.41 | +8.89% |
| 2024-05-09 | -0.49 | -0.40 | +17.70% |
| 2024-03-27 | -0.41 | -0.50 | -21.36% |
| 2023-11-09 | -0.52 | -0.48 | +7.69% |
| 2023-08-09 | -0.49 | -0.48 | +2.04% |
| 2023-05-11 | -0.54 | -0.46 | +14.81% |
| 2023-03-15 | -0.35 | -0.52 | -48.57% |
| 2022-11-10 | -0.35 | -0.54 | -54.29% |